Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis

Non ancora tradotto Non ancora tradotto
Categoria Primary study
Registry of Trialsclinicaltrials.gov
Year 2009

This article is not included in any systematic review

This article is part of the following publication threads:
Loading references information
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.
Epistemonikos ID: a042c5a2a7cbd39c5387ce03b37d2e3cf45aa6ce
First added on: Jul 30, 2018